2017
DOI: 10.1016/j.bjid.2016.10.010
|View full text |Cite
|
Sign up to set email alerts
|

Abstract: Resistance to benznidazole in certain strains of Trypanosoma cruzi may be caused by the increased production of enzymes that act on the oxidative metabolism, such as mitochondrial tryparedoxin peroxidase which catalyses the reduction of peroxides. This work presents cytotoxicity assays performed with ferrocenyl diamine hydrochlorides in six different strains of T. cruzi epimastigote forms (Y, Bolivia, SI1, SI8, QMII, and SIGR3). The last four strains have been recently isolated from triatominae and mammalian h… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0
1

Year Published

2017
2017
2021
2021

Publication Types

Select...
4

Relationship

0
4

Authors

Journals

citations
Cited by 4 publications
(2 citation statements)
references
References 29 publications
0
1
0
1
Order By: Relevance
“…Kohatsu and collaborators observed an IC50 almost three times higher in Bolivia than in Y strain and demonstrated that this compound increased the expression of the mitochondrial tryparedoxin peroxidase only in Y strain. 42 Additionally, Bolivia strain was more resistant to treatment of two nitrofurans derivatives (NF and NFOH-121) when compared to Y strain. Also, no changes at mRNA processing levels in the Bolivia strain was observed.…”
Section: Discussionmentioning
confidence: 96%
“…Kohatsu and collaborators observed an IC50 almost three times higher in Bolivia than in Y strain and demonstrated that this compound increased the expression of the mitochondrial tryparedoxin peroxidase only in Y strain. 42 Additionally, Bolivia strain was more resistant to treatment of two nitrofurans derivatives (NF and NFOH-121) when compared to Y strain. Also, no changes at mRNA processing levels in the Bolivia strain was observed.…”
Section: Discussionmentioning
confidence: 96%
“…El costo del medicamento es elevado para los gobiernos de los países en vías de desarrollo o con economía insuficiente en programas de salud, por ejemplo, en Colombia el costo anual se ha estimado en alrededor de 267 millones de dólares (WHO, 2015). Otra desventaja de los tratamientos tradicionales es la diferente susceptibilidad que han desarrollado los parásitos a estos compuestos, debido a la regulación de la expresión del gen de la adenina fosforibosiltransferasa (APRT), de la enzima lipoamido deshidrogenasa y de la tryparedoxina peroxidasa en cepas naturalmente resistentes (dos Santos et al, 2016;Kohatsu et al, 2016;García-Huertas, Mejía-Jaramillo, González, & Triana-Chavez, 2017) por lo cual, la parasitemia no puede ser eliminada; además, la respuesta terapéutica varía en función del área geográfica, debido al linaje de las cepas de T. cruzi infectantes, dado que se ha descrito diferente susceptibilidad de algunas cepas de T. cruzi al tratamiento con benznidazol, por lo que la búsqueda de nuevos tratamientos tiene una alta prioridad (Villarreal, Barnabé, Sereno, & Tibayrenc, 2004;Mejía-Jaramillo, Fernandez, Montilla, Nicholls, & Triana-Chavez, 2012).…”
unclassified